References
- Duma R. Aztreonam approved: more targeted, less toxic, than alternatives. Geriatrics. 1987; 42,
- Holloway WJ. Management of sepsis in elderly. Am J Med. 1986; 80: 143–8.
- Jones SR. Infections in frail and vulnerable elderly patients. Am J Med. 1990; 88: 30–3.
- Whelton A. Treatment of gram-negative infections in patients with renal impairment: new alternatives to aminoglycosides. J Clin Pharmacol. 1988 866–78.
- Lerner SA, Schmitt RN, Seligsohn R, Matz GJ. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med- 1986; 80: 98–104.
- Neu HC. Aztreonam’s role in the treatment of gram-negative infections. Aztreonam activity, pharmacology and clinical uses. Am J Med. 1990; 88: 2–6.
- Deger F, Douchamps J, Freschi E, Thys JP, Nevt P, Herchuelz A. Aztreonam in the treatment of serious gramnegative infections in the elderly. Int J Clin Pharmacol Ther Toxicol. 1988; 26: 22–6.
- Sattlcr FR, Schramm M, Swabb EA. Safety of aztreonam and SQ26.992 in elderly patients with renal insufficiency, Rev Infect Dis. 1985; 7: S622–7.
- Knockaert DC, Dejaeger E, Nestor L, Verbist L, Pelemans W. Aztreonam-flucloxacillin double beta-lactam treatment as empirical therapy of serious infections in very elderly patients. Age and Ageing. 1991; 20: 135–9.
- Reisberg B. The global deterioration scale: an instrument for the assessment of primary degenerative dementia. Am J Psychiatry. 1982; 139: 1136.